Latest news with #Gefion
Yahoo
6 days ago
- Health
- Yahoo
Orbis Medicines Accelerates Next-Generation Oral Macrocycle Platform with Enhanced Artificial Intelligence Capabilities of Gefion Supercomputer
Orbis begins using Gefion, Denmark's first AI supercomputer Composed of 1,528 NVIDIA H100 Tensor Core GPUs, system is optimized for large-scale, AI-driven projects Enables significant expansion of macrocycle chemical space exploration by Orbis' nGen platform New AI/ML capacity will leverage large proprietary datasets and generative AI to design novel orally available macrocycle alternatives to existing biologics COPENHAGEN, Denmark, June 03, 2025--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, and the Danish Center for AI Innovation (DCAI) today announced that Orbis has begun using Denmark's first AI supercomputer, Gefion, which is owned and operated by DCAI. Gefion will allow the company to accelerate its mission of developing oral alternatives to widely used biologics and targeting important intra- and extracellular proteins that are currently difficult or impossible to drug with orally bioavailable compounds. Orbis is pioneering the systematic discovery and development of targeted, orally available macrocycles for diseases and targets traditionally treated with biologics. The company develops compounds known as nCycles, which can address a wide range of validated protein targets with unique oral bioavailability and membrane permeability features. "Our advanced nGen platform helps us quickly create large numbers of custom-designed macrocycles with unique properties and broad medical applicability," said Orbis CEO Morten Graugaard. "By combining this platform with Gefion's computing power, we can extend beyond the nearly 140 billion compounds in our existing libraries to design entirely new collections of these molecules. This means we can explore an even broader range of chemical possibilities and more fully unlock the potential of macrocycles to improve healthcare." "Orbis' nGen platform, which has already been used to design, synthesize and test more than 700,000 individual nCycles, is an ideal application for Gefion's capabilities," said Orbis Medicines Board Chair Mikael Dolsten, M.D., Ph.D. "Combining the power of this supercomputer with our in-house target nCycle data collection, generative AI, and nCycle synthesis capabilities will accelerate the development of orally available macrocycles that have the potential to disrupt the current biologics market and provide new treatment options for patients." "Gefion is designed to deliver AI innovation at scale through immense computing power applied to the most challenging problems," said Dr. Nadia Carlsten, CEO of DCAI. "As a biomedical start-up with its own internal AI technology applied to drug design and the ability to generate vast data sets, Orbis is an ideal partner to demonstrate what Gefion can unlock when matched with specialist expertise." DCAI's Gefion supercomputer contains 1,528 NVIDIA GPUs and is optimized for large-scale AI-driven projects. Gefion enables innovators to utilize advanced computation to accelerate discovery in various fields, including biotechnology and drug discovery. Gefion has previously been used by researchers, start-ups, and large enterprises to develop new AI models and perform simulations in weather modeling, quantum computing, and business automation. About Orbis Medicines Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its nGen platform systematically delivers macrocycle candidates, termed nCycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis' pipeline is initially focused on nCycle candidates against targets validated by blockbuster biologic drugs delivered by injection. Proof-of-concept of Orbis' work has been published in Nature Communications and Nature Chemical Biology. The company has raised €116 million in venture funding to date, including a €90 million series A round led by NEA with new investors Lilly Ventures, Cormorant, EIFO and existing investors Forbion and Novo Holdings. Orbis is located in Copenhagen, Denmark and Lausanne, Switzerland. For more information, please visit: About nGen nGen is Orbis Medicines' technology platform for generating nCycles, a new class of fully synthetic macrocycle compounds optimized for oral bioavailability and membrane permeability. It consists of multiple proprietary integrated elements in a "lab in a loop" system starting with hit finding libraries of 100 billion compounds and target specific libraries designed by generative AI. The highly automated chemistry-based nGen platform can synthesize and screen up to 100,000 distinct synthetic macrocycles in weeks, allowing the company to discover candidates with the right properties to enable oral dosing and intracellular targeting. The scale and quality of the data produced from these real compounds, paired with machine learning and generative AI, creates an industry-leading platform that de-risks and accelerates development. About DCAI The Danish Centre for AI Innovation (DCAI) owns and operates Gefion, Denmark's flagship AI supercomputer, designed specifically for large-scale AI projects. Gefion ranks among the most powerful supercomputers globally powered by 1.528 NVIDIA H100 Tensor Core GPUs. DCAI's mission is to lower the barrier for accessing advanced computing capabilities, enabling customers to innovate and fostering ecosystem growth. DCAI customers include academic researchers, startups, government institutions, and enterprise customers doing large scale innovation. DCAI was formed as a company and funded by the Novo Nordisk Foundation and EIFO in 2024. View source version on Contacts Media: Matt CrensonTen Bridge Communications(917) 640-7930mcrenson@ General enquiries for DCAI & Gefion hello@ (+45) 35 27 66 00 Sign in to access your portfolio
Business Wire
6 days ago
- Business
- Business Wire
Orbis Medicines Accelerates Next-Generation Oral Macrocycle Platform with Enhanced Artificial Intelligence Capabilities of Gefion Supercomputer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, and the Danish Center for AI Innovation (DCAI) today announced that Orbis has begun using Denmark's first AI supercomputer, Gefion, which is owned and operated by DCAI. Gefion will allow the company to accelerate its mission of developing oral alternatives to widely used biologics and targeting important intra- and extracellular proteins that are currently difficult or impossible to drug with orally bioavailable compounds. Orbis is pioneering the systematic discovery and development of targeted, orally available macrocycles for diseases and targets traditionally treated with biologics. The company develops compounds known as n Cycles, which can address a wide range of validated protein targets with unique oral bioavailability and membrane permeability features. 'Our advanced n Gen platform helps us quickly create large numbers of custom-designed macrocycles with unique properties and broad medical applicability,' said Orbis CEO Morten Graugaard. 'By combining this platform with Gefion's computing power, we can extend beyond the nearly 140 billion compounds in our existing libraries to design entirely new collections of these molecules. This means we can explore an even broader range of chemical possibilities and more fully unlock the potential of macrocycles to improve healthcare.' 'Orbis' n Gen platform, which has already been used to design, synthesize and test more than 700,000 individual n Cycles, is an ideal application for Gefion's capabilities,' said Orbis Medicines Board Chair Mikael Dolsten, M.D., Ph.D. 'Combining the power of this supercomputer with our in-house target n Cycle data collection, generative AI, and n Cycle synthesis capabilities will accelerate the development of orally available macrocycles that have the potential to disrupt the current biologics market and provide new treatment options for patients.' 'Gefion is designed to deliver AI innovation at scale through immense computing power applied to the most challenging problems,' said Dr. Nadia Carlsten, CEO of DCAI. 'As a biomedical start-up with its own internal AI technology applied to drug design and the ability to generate vast data sets, Orbis is an ideal partner to demonstrate what Gefion can unlock when matched with specialist expertise.' DCAI's Gefion supercomputer contains 1,528 NVIDIA GPUs and is optimized for large-scale AI-driven projects. Gefion enables innovators to utilize advanced computation to accelerate discovery in various fields, including biotechnology and drug discovery. Gefion has previously been used by researchers, start-ups, and large enterprises to develop new AI models and perform simulations in weather modeling, quantum computing, and business automation. About Orbis Medicines Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its n Gen platform systematically delivers macrocycle candidates, termed n Cycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis' pipeline is initially focused on n Cycle candidates against targets validated by blockbuster biologic drugs delivered by injection. Proof-of-concept of Orbis' work has been published in Nature Communications and Nature Chemical Biology. The company has raised €116 million in venture funding to date, including a €90 million series A round led by NEA with new investors Lilly Ventures, Cormorant, EIFO and existing investors Forbion and Novo Holdings. Orbis is located in Copenhagen, Denmark and Lausanne, Switzerland. For more information, please visit: About n Gen n Gen is Orbis Medicines' technology platform for generating n Cycles, a new class of fully synthetic macrocycle compounds optimized for oral bioavailability and membrane permeability. It consists of multiple proprietary integrated elements in a 'lab in a loop' system starting with hit finding libraries of 100 billion compounds and target specific libraries designed by generative AI. The highly automated chemistry-based n Gen platform can synthesize and screen up to 100,000 distinct synthetic macrocycles in weeks, allowing the company to discover candidates with the right properties to enable oral dosing and intracellular targeting. The scale and quality of the data produced from these real compounds, paired with machine learning and generative AI, creates an industry-leading platform that de-risks and accelerates development. About DCAI The Danish Centre for AI Innovation (DCAI) owns and operates Gefion, Denmark's flagship AI supercomputer, designed specifically for large-scale AI projects. Gefion ranks among the most powerful supercomputers globally powered by 1.528 NVIDIA H100 Tensor Core GPUs. DCAI's mission is to lower the barrier for accessing advanced computing capabilities, enabling customers to innovate and fostering ecosystem growth. DCAI customers include academic researchers, startups, government institutions, and enterprise customers doing large scale innovation. DCAI was formed as a company and funded by the Novo Nordisk Foundation and EIFO in 2024.
Yahoo
13-05-2025
- Business
- Yahoo
AI Supercomputer Gefion welcomes new customer Kvantify to Simulate Quantum Computers
COPENHAGEN, Denmark, May 13, 2025 /PRNewswire/ -- Danish Center for AI Innovation (DCAI) is pleased to announce that Kvantify, a Danish pioneer in quantum software for chemistry and drug discovery, will be using the AI supercomputer Gefion to simulate quantum computers at scale. While Gefion has previously supported quantum computing research initiatives, Kvantify is the first dedicated quantum software company to harness its capabilities. Kvantify is leveraging Gefion's GPU-accelerated infrastructure to run and scale its novel simulator optimized for chemistry problems. Kvantify's software includes proprietary algorithms which are essential for accurately modeling molecular systems and reaction pathways relevant to drug design and enzyme engineering. "Gefion provides exaflop class performance for AI, and its specialized hardware happens to also be perfectly suited for simulated quantum computing," said Casper Kirkegaard, Head of Engineering at Kvantify. "This allows us to simulate future quantum computers today, which we are currently looking to utilize for industry relevant molecules such as penicillin using hundreds of qubits" The collaboration also highlights Gefion's broader role as an infrastructure backbone for emerging quantum R&D. As quantum technologies continue to evolve, Gefion provides the computational power needed to simulate, test, and refine quantum algorithms, enabling researchers to accelerate breakthroughs in a variety of fields—from materials science to optimization problems. "Gefion was built to push the boundaries of what's possible with AI infrastructure—and Kvantify is showing how that same AI hardware can deliver impact in quantum computing" said Nadia Carlsten, CEO of DCAI. "Their use case demonstrates how quantum software companies can meaningfully advance their work today using classical infrastructure designed for scale and specialization." "Simulating quantum computers is a fundamental step toward unlocking their real-world potential," said Hans Henrik Knudsen, CEO of Kvantify. "Gefion allows us to do this at a scale and speed we've never had before. This will directly accelerate the development of quantum algorithms and open new possibilities for future applications in science and technology." Kvantify's use of Gefion further underscores the AI supercomputer's versatility across domains beyond machine learning, including quantum simulation, molecular modeling, and next-generation HPC workflows. It also reflects a broader trend: the convergence of quantum research and classical infrastructure to solve today's most complex scientific problems. About KvantifyKvantify is a pioneering quantum software company based in Denmark. The company leverages quantum and high-performance computing to create revolutionizing solutions for complex scientific and industrial challenges. Kvantify's mission is to make quantum computing technology widely accessible, and a valuable tool for businesses worldwide. For more information, please visit ( About DCAI The Danish Centre for AI Innovation (DCAI) owns and operates Gefion, Denmark's flagship AI supercomputer, designed specifically for large-scale AI projects. Gefion ranks among the most powerful supercomputers globally powered by 1.528 NVIDIA H100 Tensor Core GPUs. DCAI's mission is to lower the barrier for accessing advanced computing capabilities, enabling customers to innovate and fostering ecosystem growth. DCAI customers include academic researchers, startups, government institutions, and enterprise customers doing large scale innovation. DCAI was formed as a company and funded by the Novo Nordisk Foundation and EIFO in 2024. View original content: SOURCE Danish Centre for AI Innovation (DCAI) Sign in to access your portfolio
&w=3840&q=100)
Business Standard
28-04-2025
- Business
- Business Standard
Will AI help Denmark avoid its Nokia moment as Ozempic boom starts fading?
Remember Nokia Oyj, Finland's economic miracle that turned to dust? The Danes do. Their own mini-boom of recent years has been largely fueled by one firm, Ozempic maker Novo Nordisk A/S, whose diabetes and weight-loss medications are under competitive assault from US rival Eli Lilly & Co. Novo's share price has halved in six months; it's given up its crown of Europe's most valuable firm to SAP SE. This reflects deflating hype rather than a crisis. Novo sales are still forecast to grow at double-digit rates this year, according to Bloomberg Intelligence, with Denmark's economy set to grow above the European average. But throw in the risk of a Trump tariff war over Greenland, and you can see why there's more fear than there used to be of a Nokia moment in a small export-reliant country of 6 million whose multinationals like AP Moller Maersk A/S and Vestas Wind Systems A/S punch well above their weight. 'I'm starting to get worried,' says Martin Jes Iversen, a professor at the Copenhagen Business School, whose research shows a small group of very big firms — including Novo — has become critical to the economy. Novo's disproportionate share of profits and research spending was also highlighted by University of Virginia Professor Herman Mark Schwartz in a 2023 essay called The Nokia Risk, which warned that Denmark lacked the kind of home-grown artificial-intelligence firms that might drive more disruptive innovation. Hence why it's encouraging to see the spoils of Denmark's Ozempic success being reinvested in potentially more future-proof projects like the recently unveiled supercomputer Gefion. Designed specifically for big AI projects, Gefion — named after the Norse goddess of fertility — was funded to the tune of $87 million by Novo's nonprofit foundation, the firm's majority voting shareholder, in partnership with Nvidia Corp., which supplied the chips. Aside from the optics of spreading the Ozempic wealth around, this supercomputer opens up potential for AI research and startups in Denmark and Europe, which is desperate to attract talent and reverse years of disappointing growth. One startup, used Gefion as part of a pilot access scheme to crunch data for tech that helps nurses monitor patients and cut workload; Chief Executive Officer Mikkel Wad Thorsen tells me computing power is a scarce resource and that Gefion is a sign Denmark is taking AI seriously. And while the potential for AI in drug discovery and eradicating disease is a much-hyped and far-off thing, it should also be noted that Gefion is part of a national plan to widen and streamline research access to Danes' health data, which was one of the recommendations in Mario Draghi's report to pull Europe out of its 'slow agony.' This isn't just for Novo's benefit — the Gefion investment was at arm's length and carries no ownership rights — but there might be positive spillover effects of this kind of research for Danish and European health care. In the short term, there isn't much to move the needle here for stressed-out shareholders of Novo and other big Danish companies. The more obvious defences that Denmark has against a trade shock are its government budget surplus and its 'flexicurity' model that combines flexibility on corporate layoffs with a secure social safety net. That and the hope that being highly exposed to pharmaceuticals isn't quite the same risk as being exposed to cellphones and paper mills, which Danske Bank economist Las Olsen says exacerbated Finland's post-Nokia blues. Longer term, though, Danes will be hoping that Gefion and other projects like the robotics hub of Odense serve as a hedge against chaos. It could mean more researchers, more tech brains and more productivity gains on a continent desperately in need of all three. Maybe building geopolitical muscle is a surprise side effect of losing weight via Ozempic.
